The peptide story is no longer confined to pharma. Consumer interest has exploded, and search data provide a visible demand indicator, but do not by themselves establish clinical evidence or sustained purchasing. As of April 2026, "peptide therapy" interest rose 281% year-over-year on Google, 459% on TikTok and 412% on Instagram (Spate, via Glossy). Co-search terms reveal the underlying motivation: NAD (+601%), GLP-1 (+177%) and anti-aging (+162%) — all expressions of one desire to slow or reverse aging.
Pulsar's 2026 audience mapping shows five distinct movements, each pulling a different demographic: (1) weight-loss GLP-1s — the largest, ~60% of search volume; (2) healing/recovery peptides (BPC-157, TB-500) in the athlete/active community; (3) longevity (epithalon, GHK-Cu, thymosin alpha-1) among high-income, evidence-minded consumers; (4) performance GH peptides; and (5) cognitive nootropics (semax, selank). GHK-Cu is the breakout: search interest up over 1,000% YoY, crossing from niche skincare into mainstream longevity, helped by features in TIME and MIT Technology Review.
For ingredient suppliers, the most actionable territory is beauty and personal care. The beauty industry is flooding the market with peptide products — building on the K-18 / peptide hair-repair precedent (acquired by Unilever for >$1B in 2023) and the K-beauty familiarity with topical peptides. 2026 launches include P&G's Ouai $50 hair "Bond Repair Balm," Neurogan's 2% GHK-Cu body care (32.8% wrinkle-depth reduction in a 12-week trial), and Symrise / BASF active launches at in-cosmetics Global. The opportunity: credible, topically-delivered peptides with thick clinical evidence (GHK-Cu, Matrixyl, hydrolysed collagen) are settling into mainstream anti-aging stacks, while "needle-free" and menopause need-states are wide open.
The risk to manage is the evidence gap. Search volume moves independently of proof: BPC-157 and TB-500 rest largely on animal data, and FDA restriction followed the gap. Brands that lead with trials and credible sources may be better positioned as scrutiny increases; those that over-claim on thin-evidence compounds face trust and regulatory pressure. For B2B suppliers, that means differentiate on documented efficacy, consistent purity, and claim-ready dossiers — and avoid enabling the self-source / self-inject grey market, which is the least brand-safe behaviour in the category.
B2B buyer takeaways
- The cited search datasets show measurable consumer interest — search up 281% (Google) / 459% (TikTok) YoY as of Apr 2026.
- Beauty and personal care may offer a comparatively lower-risk B2B area, subject to ingredient, claims, evidence and destination-market requirements.
- GHK-Cu shows strong reported search growth in the cited dataset (+1,000%); commercial decisions should also consider evidence, claims and destination-market rules; stock evidence-backed, topically-delivered actives.
- Differentiate on proof and purity; the evidence gap is the category's biggest reputational risk — avoid grey-market enablement.
Sources & References
1. Pulsar Platform, "Mapping the peptide audiences (2026)" https://audiences.pulsarplatform.com/mapping-the-peptide-audiences-2026
2. Glossy, "The beauty industry welcomes a flood of new peptide products as 'peptide therapy' trends online" https://www.glossy.co/beauty/the-beauty-industry-welcomes-a-flood-of-new-peptide-products-as-peptide-therapy-trends-online
3. Peptide News Digest, "The Most Popular Peptides of 2026" (GHK-Cu, BPC-157) https://peptidenewsdigest.org/insights/trending-peptides-april-2026
4. Tetrapod Beauty, "Peptide Therapy Searches Up 281% on Google (2026 trend peak)" https://tetrapod.beauty/en/news/peptide-therapy-search-281pct-google-trend-2026
5. VitalityPeptideLabs, "The Rise of Peptides: Why Interest Is Growing Rapidly" https://www.vitalitypeptidelabs.com/post/the-rise-of-peptides-why-interest-is-growing-rapidly
Editorial summary of third-party reporting only; not legal, medical, investment or regulatory advice. Figures, market estimates and regulatory statements reflect the cited source and publication date, and should be rechecked for the relevant product, jurisdiction and intended use.